{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825893477460736.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/0016-5085(91)90599-g"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:001650859190599G?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:001650859190599G?httpAccept=text/plain"}}],"dc:title":[{"@value":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825893477460738","@type":"Researcher","foaf:name":[{"@value":"Anna S.F. Lok"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893477460740","@type":"Researcher","foaf:name":[{"@value":"Raymond H.S. Liang"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893477460736","@type":"Researcher","foaf:name":[{"@value":"Edmond K.W. Chiu"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893477460741","@type":"Researcher","foaf:name":[{"@value":"Kee-Lam Wong"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893477460737","@type":"Researcher","foaf:name":[{"@value":"Tai-Kwong Chan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893477460739","@type":"Researcher","foaf:name":[{"@value":"David Todd"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00165085"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00165085"},{"@type":"PISSN","@value":"https://id.crossref.org/issn/00165085"}],"prism:publicationName":[{"@value":"Gastroenterology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"1991-01","prism:volume":"100","prism:number":"1","prism:startingPage":"182","prism:endingPage":"188"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:001650859190599G?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:001650859190599G?httpAccept=text/plain"}],"createdAt":"2016-06-10","modifiedAt":"2020-09-22","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002218323019648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231298215040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232280833152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693322566144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Novel monitoring of hepatitis B reactivation based on ultra‐high sensitive hepatitis B surface antigen assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710734319232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711733152384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643855095552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294740489334912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905605133824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565170753082880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B Virus Reactivation by Immunosuppressive Therapy in Patients with Autoimmune Diseases: Risk Analysis in Hepatitis B Surface Antigen-negative Cases"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181473724928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185478217984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Fatal reactivation of hepatitis B virus infection in a patient with adult T‐cell leukemia–lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185479120640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical evaluation of a novel and highly sensitive immunoassay for anti‐hepatitis B core antigen using a fully automated immunochemical analyzer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568466082640384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256755584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846642463453952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848655117244800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656232379136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Association of hepatitis B with antirheumatic drugs: a case–control study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660454235392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis <scp>B</scp> virus in a patient with adult <scp>T</scp>‐cell leukemia–lymphoma receiving the anti‐<scp>CC</scp> chemokine receptor 4 antibody mogamulizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687689344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Changes in levels of hepatitis B virus markers in patients positive for low‐titer hepatitis B surface antigen"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204704854656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Reactivation in a Multiple Myeloma Patient with Resolved Hepatitis B Infection during Bortezomib Therapy : Case Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204790262400","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A non-Hodgkin lymphoma patient with reactivation of HBV during chemotherapy and emergence of a YMDD-motif mutant on lamivudine, eventually controlled by adfovil dipovoxil"},{"@language":"ja","@value":"ＮＨＬに対する化学療法中にＹＭＤＤ変異によりＨＢＶ再活性化をきたし，ａｄｅｆｏｖｉｒ　ｄｉｐｉｖｏｘｉｌ追加投与にて改善した１例"},{"@value":"症例報告 NHLに対する化学療法中にYMDD変異によりHBV再活性化をきたし,adefovir dipivoxil追加投与にて改善した1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク NHL ニ タイスル カガク リョウホウチュウ ニ YMDD ヘンイ ニ ヨリ HBV サイカッセイカ オ キタシ adefovir dipivoxil ツイカ トウヨ ニテ カイゼンシタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795610880","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis"},{"@language":"ja","@value":"免疫抑制・化学療法により発症するＢ型肝炎対策：厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告"},{"@language":"ja-Kana","@value":"メンエキ ヨクセイ カガク リョウホウ ニ ヨリ ハッショウスル Bガタ カンエン タイサク コウセイ ロウドウショウ ナンチセイ ノ カン タンドウ シッカン ニ カンスル チョウサ ケンキュウ ハン ゲキショウ カンエン ブンカカイ オヨビ カンコウヘン オ フクメタ ウイルスセイ カン シッカン ノ チリョウ ノ ヒョウジュンカ ニ カンスル ケンキュウ ハン ゴウドウ ホウコク"},{"@value":"Prevention of immunosuppressive therapy or chemotherapy‐induced reactivation of hepatitis B virus infection: joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204870882688","@type":"Article","resourceType":"エディトリアル(editorial)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Fatal HBV Reactivation in a Subject with Anti-HBs and Anti-HBc"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204872779136","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Anti-HBs-Positive Liver Failure Due to Hepatitis B Virus Reactivation Induced by Rituximab"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205056313984","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Reactivation of Hepatitis B Virus After Glioblastoma Treatment With Temozolomide  -Case Report-"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770766080","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with membranous nephropathy treated with immunosuppression"},{"@value":"膜性腎症の治療経過中に発症したde novo B型肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク マクセイジンショウ ノ チリョウ ケイカ チュウ ニ ハッショウ シタ de novo Bガタ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770778880","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Automated risk management of HBV reactivation by encoding patients' medical records"},{"@language":"ja","@value":"診療情報コード化による自動的HBV再活性化リスクマネージメント"},{"@language":"ja-Kana","@value":"シンリョウ ジョウホウ コードカ ニ ヨル ジドウテキ HBV サイカッセイカ リスクマネージメント"},{"@value":"Automated risk management of HBV reactivation by encoding patients^|^apos; medical records"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772239360","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B virus reactivation presented at 10 months after the last R-CHOP therapy against malignant lymphoma: A case report"},{"@language":"ja","@value":"リツキシマブ投与終了10カ月後に発症したHBV再活性化de novo肝炎の1例"},{"@value":"症例報告 リツキシマブ投与終了10カ月後に発症したHBV再活性化de novo肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク リツキシマブ トウヨ シュウリョウ 10カゲツ ゴ ニ ハッショウ シタ HBV サイカッセイカ de novo カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390566775140586496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Fulminant Hepatitis due to <i>de novo</i> Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1390857669061603712","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Construction of Protocol-Based Pharmacotherapy Management (PBPM) Using an Electronic Medical Record Interlocking Support System to Prevent Hepatitis B Virus Reactivation Induced by Cancer Chemotherapy"},{"@language":"ja","@value":"がん化学療法によるB型肝炎再活性化予防のための電子カルテ連動支援システムを用いたPBPMの構築"}]},{"@id":"https://cir.nii.ac.jp/crid/1391975276375902208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367073795072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/0016-5085(91)90599-g"},{"@type":"CROSSREF","@value":"10.1007/s10157-011-0464-7_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.00998.x_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1007/s10147-011-0294-3_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.4190-19_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2176/nmc.51.728_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.45.1590_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.45.0158_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.3899/jrheum.110289_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/liv.13349_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.01073.x_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1182/asheducation-2014.1.576_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.4445-20_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2957/kanzo.48.309_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.74_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.3960/jslrt.52.67_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1002/jgh3.12636_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/hepr.13761_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1016/j.aohep.2024.101764_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1007/s12185-015-1750-z_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/hepr.12513_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/hepr.13229_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1007/s12072-019-09988-7_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.194_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2014.04.033_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1168-2_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1093/cid/civ344_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1002/jmv.21995_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1007/s10165-012-0709-7_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/hepr.12117_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.01039.x_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2957/kanzo.50.38_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.48.9_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.91_references_DOI_T6ZV84yfIDmBVgRsrLnh6FvnCqG"}]}